Post-effective Amendment to an S-8 Filing (s-8 Pos)

As filed with the Securities and Exchange Commission on February 24, 2017

 

Registration No. 333-127527

Registration No. 333-192848

Registration No. 333-197497

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-127527

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-192848

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-197497

 

DERMA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware		23-2328753
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)
214 Carnegie Center, Suite 300
Princeton, NJ		08540
(Address of Principal Executive Offices)		(Zip Code)

 

Derma Sciences, Inc. Amended and Restated Stock Option Plan

Amended and Restated Derma Sciences, Inc. 2012 Equity Incentive Plan

Derma Sciences, Inc. Restricted Stock Plan

(Full title of the plans)

 

Richard D. Gorelick, Esq., Secretary 

214 Carnegie Center, Suite 300

Princeton, NJ 08540

[phone]

(Name, address and telephone number, including area code, of agent for service)

 

Copies to:

Bradley Faris, Esq. 

Latham & Watkins LLP

 330 N. Wabash Ave.

Suite 2800

Chicago, Illinois 60611

[phone]

Counsel to Registrant

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨	Accelerated filer x	Non-accelerated filer ¨	Smaller reporting company ¨
		(Do not check if a smaller reporting company)

 

 

---

 

 

EXPLANATORY NOTE: DEREGISTRATION OF SECURITIES

 

This Post-Effective Amendment to Form S-8 relates to the following Registration Statements of Derma Sciences, Inc., a Delaware corporation (the “ Registrant ”), on Form S-8 (collectively, the “ Registration Statements ”):

 

·

Registration Statement No. 333-127527, filed with the Securities and Exchange Commission (the “ Commission ”) on August 15, 2005, as amended by the Post-Effective Amendment filed on May 20, 2010, registering the offer and sale of (i) 1,457,001 shares of common stock, par value $0.01 per share (the “ Common Stock ”), of the Registrant issuable pursuant to the Derma Sciences, Inc. Amended and Restated Stock Option Plan (the “ Stock Option Plan ”) and (ii) 21,875 shares of Common Stock issuable pursuant to the Derma Sciences, Inc. Restricted Stock Plan (the “ Restricted Stock Plan ”), and such additional shares of Common Stock as may be issuable pursuant to such plans as a result of future stock splits, stock dividends or similar transactions;

 

·

Registration Statement No. 333-192848, filed with the Commission on December 13, 2013, registering the offer and sale of 4,500,000 shares of Common Stock of the Registrant issuable pursuant to the Amended and Restated Derma Sciences, Inc. 2012 Equity Incentive Plan (the “ Equity Incentive Plan ” and, together with the Stock Option Plan and the Restricted Stock Plan, the “ Plans ”) and such additional shares of Common Stock as may be issuable pursuant to the Equity Incentive Plan as a result of future stock splits, stock dividends or similar transactions; and

 

·

Registration Statement No. 333-197497, filed with the Commission on July 18, 2014, registering the offer and sale of an additional 1,500,000 shares of Common Stock of the Registrant issuable pursuant to the Plan and such additional shares of Common Stock as may be issuable pursuant to the Equity Incentive Plan as a result of future stock splits, stock dividends or similar transactions.

 

This Post-Effective Amendment to the Registration Statements is being filed solely for the purpose of deregistering any and all securities registered under the Registration Statements that remain unsold. On January 10, 2017, the Registrant entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among the Registrant, Integra Derma, Inc., a Delaware corporation (the “ Purchaser ”), and Integra LifeSciences Holdings Corporation, a Delaware corporation and parent company of the Purchaser (the “ Parent ”), pursuant to which the Purchaser offered to purchase all outstanding shares of Common Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock of the Registrant (the “ Offer ”).

 

On February 24, 2017, following the expiration of the Offer and pursuant to the terms of the Merger Agreement, Purchaser was merged with and into the Registrant with the Registrant continuing as the surviving corporation after the merger (the “ Merger ”). As a result of the Merger, the Common Stock is held of record by fewer than 300 persons. Accordingly, the Registrant intends to file a Certification and Notice of Termination of Registration on Form 15 with the Commission with respect to its Common Stock. As a result of the Merger, no additional shares of Common Stock will be issued under the Plans.

 

In light of the foregoing, the Registrant has determined to terminate the offerings under the Registration Statements. Accordingly, the Registrant is filing this Post-Effective Amendment to the Registration Statements pursuant to Rule 478 under the Securities Act of 1933, as amended, to terminate the effectiveness of the Registration Statements, and, in accordance with the undertakings made by the Registrant in the Registration Statements, to remove from registration any and all of the securities previously registered under the Registration Statements that remain unsold as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of all such securities.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, State of New Jersey, on the 24th day of February, 2017.

 

	DERMA SCIENCES, INC.
	By:	/s/ Peter J. Arduini
		Name:	Peter J. Arduini
		Title:	President and Chief Executive Officer

 

No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933, as amended.